Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of CanSino's COVID-19 mRNA Vaccine (CS-2034) in Adults
NCT05373472Phase 2Completed
- Sponsor
- CanSino Biologics Inc.
- Start
- Jul 2022
- Primary completion
- Sep 2022
- Modality
- Vaccine mRNA, Lipid-based Nanoparticles, mRNA Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of CS-2034 in coronavirus disease 2019 (COVID-19), sponsored by CanSino Biologics Inc.. Started Jul 2022; status: completed.
02
Drugs
CS-2034
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05373472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05373472.